Vilin Bio Med Q2 FY27 Share Price & Earnings Call Analysis

₹50.55+0.50% today
Market cap
₹77 Cr
P/E
39.95
ROE
7.51%
PEG
2.56
Price to sales
1.83
Debt to equity
0.01
52W high / low
₹38.4 / ₹19.0
Sales growth (5Y)
29.64%
EBITDA margin
7.57%
Net profit margin
4.57%
Promoter holding
56.65%
Sales (last year)
₹42 Cr

Incorporated in 2005, Vilin Bio Med Ltd is in the business of manufacturing and selling of pharmaceutical products[1]

Potential multibaggers · Q2 FY27

Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance

  1. Strong growth
    2
  2. 1
  3. 3

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Vilin Bio Med shareholding (Sep 2026)

Promoters

56.65%

unchanged QoQ

FIIs

0.13%

+0.13 pp QoQ

DIIs

—

— QoQ

Public

43.22%

−0.13 pp QoQ

Peers

Pharmaceuticals & Biotechnology companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Up 2%+₹3,142 Cr34.2
240%+Up 2%+₹489 Cr16.7
340%+Up 0–2%₹234 Cr17.8
440%+Flat₹18,464 Cr1614.0
540%+Flat₹9,050 Cr34.8
640%+Flat₹4,493 Cr—

Financials of Vilin Bio Med

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Shareholder Pattern

Vilin Bio Med

Shareholding breakup across reporting periods.

Jun 2023Sep 2023Mar 2024Sep 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Promoters +90.45%64.52%64.52%64.09%63.89%63.89%63.89%63.65%59.57%56.65%56.65%
FIIs +0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.13%
Public +9.55%35.48%35.48%35.91%36.11%36.11%36.11%36.35%40.43%43.35%43.22%
No. of Shareholders21659585581551492476462397382384

Financials of Vilin Bio Med

Quarterly Results

Quarter-by-quarter operating performance

No quarterly results data available for this company yet.

Financials of Vilin Bio Med

Profit & Loss

Annual income statement trend

Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales +16.6211.5411.2112.3115.8014.8142.2665.20
Sales growth-30.57%-2.86%+9.81%+28.35%-6.27%+185.35%+226.33%
Expenses +15.7110.6810.449.7314.9714.0239.0660.38
Operating Profit0.910.860.772.580.830.793.204.82
OPM %5.48%7.45%6.87%20.96%5.25%5.33%7.57%7.39%
Other Income +0.010.000.000.020.320.470.000.00
Interest0.410.440.510.650.790.850.070.00
Depreciation0.310.260.220.170.130.100.280.41
Profit before tax0.200.160.041.780.230.312.854.41
Tax %20.00%25.00%25.00%30.34%26.09%25.81%31.93%
Net Profit +0.160.120.031.250.160.221.933.06
EPS in Rs0.160.120.031.260.110.161.272.01
Dividend Payout %0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Financials of Vilin Bio Med

Balance Sheet

Capital structure and asset base

Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 2026
Equity Capital3.303.303.309.9513.9513.9515.2515.25
Reserves3.944.064.100.738.899.1113.1214.40
Borrowings +4.535.525.304.936.832.570.210.04
Other Liabilities +2.241.010.862.072.732.156.369.75
Total Liabilities14.0113.8913.5617.6832.4027.7834.9439.44
Fixed Assets +2.131.871.651.511.381.282.873.05
CWIP0.000.000.000.000.001.570.000.00
Investments0.000.000.000.000.000.000.000.02
Other Assets +11.8812.0211.9116.1731.0224.9332.0736.37
Total Assets14.0113.8913.5617.6832.4027.7834.9439.44

Financials of Vilin Bio Med

Cash Flows

Operating, investing and financing cash movement

Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +-1.46-1.000.21-1.66-7.420.210.70
Cash from Investing Activity +-0.020.000.00-0.030.32-1.11-0.30
Cash from Financing Activity +1.510.98-0.221.688.87-5.101.01
Net Cash Flow0.03-0.02-0.010.001.77-5.991.41
Free Cash Flow-1.48-1.000.21-1.69-7.42-1.360.40
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit-156%-112%29%-43%-888%35%49%

Financials of Vilin Bio Med

Ratios

Working capital efficiency and return ratios

Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days159.66241.96253.64166.04131.22210.97137.85
Inventory Days56.1383.1793.8244.74125.41119.5070.03
Days Payable49.4833.1126.3460.4954.7139.0232.59
Cash Conversion Cycle166.31292.03321.13150.28201.91291.44175.29
Working Capital Days110.91204.32211.6445.0776.23374.61168.16
ROCE %4.87%4.30%17.17%4.51%4.20%10.77%

Vilin Bio Med: frequently asked questions

What is Vilin Bio Med share price today?

Vilin Bio Med last traded at ₹50.55, with a market capitalisation of ₹77 Cr and a P/E ratio of 40.0.

What is the promoter holding in Vilin Bio Med?

Promoters held 56.65% of Vilin Bio Med in Sep 2026 (unchanged versus Jun 2026).

How much do FIIs and DIIs hold in Vilin Bio Med?

In Sep 2026, foreign institutional investors held 0.13% and domestic institutions (including mutual funds) held — of Vilin Bio Med.

What is Vilin Bio Med's ROE and ROCE?

Vilin Bio Med's return on equity is 7.51% and its return on capital employed is 10.8%.

Does Vilin Bio Med pay a dividend?

Vilin Bio Med's dividend yield is 0% at the current price; see the Vilin Bio Med dividends page for past payouts.

Which sector does Vilin Bio Med belong to?

Vilin Bio Med is in the Pharmaceuticals & Biotechnology sector. Its peer comparison and sector ranking are on this page.

What did Vilin Bio Med's management say on the latest earnings call?

Arthneeti's analysis of the Q2 FY27 earnings call covers revenue, margins, capex and fundraising guidance from Vilin Bio Med's management.

How does Arthneeti AI analyse Vilin Bio Med?

Arthneeti reads Vilin Bio Med's earnings call transcripts and filings and scores revenue growth, margins, capex and fundraising, then ranks the company against its sector.

What Vilin Bio Med's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Lasa Supergeneri (Q2 FY27)

    306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra

  • Themis Medicare (Q2 FY27)

    Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q

  • Panacea Biotec (Q2 FY27)

    September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Biofil Chemicals (Q2 FY27)

    Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem